US › Healthcare

Capricor Therapeutics Inc (CAPR)

US · Healthcare · Biotechnology

$9.42+10.05%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

Net profit

$-40.7M

EPS

$-0.70

EPS estimate

$-0.58

EPS came in at -0.70 against a street estimate of -0.58 — a miss of 20.7%.

Key statistics

Market cap

$486.6M

Forward P/E

78.7

P/B

1.98

Book value

$4.24

EPS (TTM)

$-2.45

52-week high

$40.37

52-week low

$2.96

50-day MA

$11.32

200-day MA

$23.43

Beta

0.72

Analyst view

Analysts rate Capricor Therapeutics Inc a strong buy (8 buy, 0 hold, 0 sell out of 8) with an average price target of $28.50.

Shareholding

Insiders

9.44%

Institutions

76.20%

Largest institutional holders

Fund	Stake
Suvretta Capital Management, LLC	6.57%
BlackRock Inc	5.89%
TANG CAPITAL MANAGEMENT LLC	5.85%
State Street Corp	3.75%
Vanguard Capital Management, LLC	3.49%
RA Capital Management, LLC	2.59%
Geode Capital Management, LLC	1.92%
The Goldman Sachs Group Inc	1.57%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Capricor Therapeutics Inc — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.